58481-06-4

Basic information

• Product Name: 4-Pyridinecarboxylicacid,2-phenyl-,hydrazide(9CI)
• Synonyms: 4-Pyridinecarboxylicacid,2-phenyl-,hydrazide(9CI)
• CAS NO: 58481-06-4
• Molecular Formula: C₁₂H₁₁N₃O
• Molecular Weight: 213.2352
• Product Categories: HYDRAZINE
• Mol File: 58481-06-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.215 g/cm³
• Refractive Index: 1.617
• CAS DataBase Reference: 4-Pyridinecarboxylicacid,2-phenyl-,hydrazide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarboxylicacid,2-phenyl-,hydrazide(9CI)(58481-06-4)
• EPA Substance Registry System: 4-Pyridinecarboxylicacid,2-phenyl-,hydrazide(9CI)(58481-06-4)

Safety Data

• Hazardous Substances Data: 58481-06-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H11N3O/c13-15-12(16)10-6-7-14-11(8-10)9-4-2-1-3-5-9/h1-8H,13H2,(H,15,16)

Upstream product

• 92199-59-2 ethyl 2-phenylpyridine-4-carboxylate 
• 55240-51-2 2-phenylpyridine-4-carboxylic acid 
• 92290-75-0 2-chloro-6-phenyl-isonicotinic acid ethyl ester 
• 1045325-76-5 2-chloro-6-phenylisonicotinoyl chloride 

Downstream Products

• 1312025-79-8 potassium 2-(2-phenylisonicotinoyl)hydrazinecarbodithioate 
• 837371-88-7 5-(1-oxy-pyridin-4-yl)-3-(2-phenyl-pyridin-4-yl)-1,2,4-triazole 

Relevant articles and documents

Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia

Our previous study identified 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4]triazol-3-yl]-benzonitrile (2) as a safe and potent xanthine oxidoreductase (XOR) inhibitor for the treatment of hyperuricemia. Here, we synthesized a series of 3,5-dipyridyl-1,2,4-triazole derivatives and, in particular, examined their in vivo activity in lowering the serum uric acid levels in rats. As a result, we identified 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole (FYX-051, compound 39) to be one of the most potent XOR inhibitors; it exhibited an extremely potent in vivo activity, weak CYP3A4-inhibitory activity and a better pharmacokinetic profile than compound 2. Compound 39 is currently being evaluated in a phase 2 clinical trial.